Alerts will be sent to your verified email
Verify Email
VENUSREM
|
Venus Remedies
|
Brooks Laboratories
|
Lyka Labs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
6.64 % | -23.88 % | 145.3 % |
|
5yr average Equity Multiplier
|
1.46 | 1.78 | -0.06 |
|
5yr Average Asset Turnover Ratio
|
0.89 | 0.6 | 0.64 |
|
5yr Avg Net Profit Margin
|
4.93 % | -23.79 % | -21.64 % |
|
Price to Book
|
0.82 | 6.71 | 3.97 |
|
P/E
|
11.63 | 0.0 | 95.49 |
|
5yr Avg Cash Conversion Cycle
|
72.13 Days | -10.34 Days | 16.94 Days |
|
Inventory Days
|
93.66 Days | 93.5 Days | 26.54 Days |
|
Days Receivable
|
47.69 Days | 66.75 Days | 77.33 Days |
|
Days Payable
|
52.51 Days | 179.8 Days | 133.6 Days |
|
5yr Average Interest Coverage Ratio
|
176.34 | -11.84 | 0.6 |
|
5yr Avg ROCE
|
6.96 % | -15.03 % | 22.35 % |
|
5yr Avg Operating Profit Margin
|
10.58 % | -13.23 % | 20.24 % |
|
5 yr average Debt to Equity
|
0.22 | 0.21 | -0.79 |
|
5yr CAGR Net Profit
|
n/a | 0.22 % | -47.18 % |
|
5yr Average Return on Assets
|
5.11 % | -14.62 % | -5.63 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
41.76 % | 52.62 % | 58.16 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.95 % | -13.79 % | 10.37 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 9.9 % | -0.72 % |
|
Venus Remedies
|
Brooks Laboratories
|
Lyka Labs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
Location Wise Break-Up
|